Pliant Therapeutics, Inc. (NASDAQ:PLRX) Stock Has Consensus Price Target of $3.00 According to Analysts

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) have earned a consensus recommendation of “Reduce” from the four ratings firms that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $3.00.

A number of analysts have weighed in on PLRX shares. Weiss Ratings restated a “sell (e+)” rating on shares of Pliant Therapeutics in a report on Friday, July 17th. Wall Street Zen raised Pliant Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th.

Pliant Therapeutics Stock Performance

NASDAQ PLRX opened at $1.02 on Wednesday. The company has a market cap of $63.16 million, a P/E ratio of -0.68 and a beta of 1.27. The business’s 50 day moving average price is $1.10 and its 200-day moving average price is $1.16. Pliant Therapeutics has a fifty-two week low of $0.97 and a fifty-two week high of $1.95.

Pliant Therapeutics (NASDAQ:PLRX) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.02). As a group, equities analysts predict that Pliant Therapeutics will post -1.42 EPS for the current year.

Hedge Funds Weigh In On Pliant Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Spark Investment Management LLC bought a new stake in shares of Pliant Therapeutics in the 2nd quarter valued at about $26,000. Headlands Technologies LLC bought a new position in shares of Pliant Therapeutics during the 2nd quarter worth approximately $38,000. Stonepine Capital Management LLC bought a new position in shares of Pliant Therapeutics during the 2nd quarter worth approximately $262,813. Public Employees Retirement System of Ohio purchased a new stake in Pliant Therapeutics during the second quarter valued at approximately $32,000. Finally, ADAR1 Capital Management LLC purchased a new stake in Pliant Therapeutics during the second quarter valued at approximately $6,281,000. 97.30% of the stock is currently owned by institutional investors.

About Pliant Therapeutics

Pliant Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic diseases. The company uses its expertise in integrin biology to discover and develop medicines intended to address the underlying mechanisms that contribute to tissue scarring and organ dysfunction.

Pliant’s leading investigational product is bexotegrast, an oral, small-molecule inhibitor designed to selectively target the alphaVbeta6 and alphaVbeta1 integrins. The therapy has been studied in conditions including idiopathic pulmonary fibrosis, a progressive lung disease, and primary sclerosing cholangitis, a chronic liver disease.